Main container

“Randomized, Controlled, Open-label, Phase IIb/III Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Patients with Metastatic Leiomyosarcoma

Title
“Randomized, Controlled, Open-label, Phase IIb/III Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Patients with Metastatic Leiomyosarcoma
Code
PM1183-C-010-22
Type
Sperimentale con farmaco
Start Year
2024
Status
In Corso

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in

Clinical Trial
A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors
Read more
Clinical Trial
Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors
Read more
Content updated
18/03/2024 14:18